Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.

被引：0
|
作者：
Lago, Nieves Martinez
Gonzalez, Borja
Martin, Elena Gallardo
Montes, Ana Fernandez
Castineira, Antia Cousillas
Suarez, Begona Grana
Maseda, Alberto Carral
Augusto, Maria Luz Pellon
Villarroel, Paula Gonzalez
Gomez, Juan De La Camara
Fernandez, Mercedes Salgado
Lopez, Margarita Reboredo
机构：
[1] Complexo Hosp Univ Ferrol, Ferrol, Spain
[2] Hosp Univ Lucus Augusti, Lugo, Spain
[3] Alvaro Cunqueiro Hosp, Vigo, Spain
[4] Complexo Hosp Univ Ourense CHUO, Dept Med Oncol, Orense, Spain
[5] Complejo Hosp Pontevedra, Med Oncol Dept, Pontevedra, Spain
[6] Univ Hosp A Coruna, La Coruna, Spain
[7] Hosp Univ Lucus Augusti, Med Oncol Dept, Lugo, Spain
[8] Complexo Hosp Univ Ourense, Orense, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
613-135-2370-5109; 281-5277-2560; 613-135-2370-7650-2700; 283-2494; 283-237-255; 261-492-199; 613-135-244-3829-325; 4; 3; 2; 182; 239; 16; 6; 5; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.51
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [21] Analysis of prognostic factors on trifluridine-tipiracil plus bevacizumab treatment in metastatic colorectal cancer: A retrospective real-world analysis
    Onishi, M.
    Hirose, T.
    Shoji, H.
    Okita, N. T.
    Hirano, H.
    Takashima, A.
    Kato, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1441 - S1441
  • [22] Pooled safety and efficacy analysis of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC) using individual patient data (IPD) from five clinical trials
    Yamazaki, K.
    Yamada, T.
    Kuboki, Y.
    Oki, E.
    Yoshino, T.
    Hamano, T.
    Kawakami, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S28 - S28
  • [23] Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
    Yamazaki, K.
    Satake, H.
    Takashima, A.
    Mizusawa, J.
    Kataoka, T.
    Fukuda, H.
    Ishizuka, Y.
    Suwa, Y.
    Numata, K.
    Shibata, N.
    Asayama, M.
    Yokota, M.
    Tsushima, T.
    Ohta, T.
    Yamaguchi, T.
    Hamaguchi, T.
    Kanemitsu, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S738 - S738
  • [24] Multicenter retrospective study of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT).
    Mitani, Seiichiro
    Kito, Yosuke
    Kawakami, Hisato
    Nishina, Shinichi
    Matsumoto, Toshihiko
    Tsuzuki, Takao
    Shinohara, Yudai
    Shimokawa, Hozumi
    Kumanishi, Ryosuke
    Ohta, Takashi
    Kimura, Shinya
    Kawakami, Takeshi
    Nishina, Tomohiro
    Hasegawa, Hiroko
    Akiyoshi, Kohei
    Chiba, Yasutaka
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 121 - 121
  • [25] Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)
    Calvo Ferrandiz, A.
    Dahan, L.
    Hollebecque, A.
    Prager, G.
    Andre, T.
    Argiles Martinez, G.
    Bordonaro, R.
    Stein, A.
    Tortora, G.
    Leger, C.
    Amellal, N.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Martinez-Lago, Nieves
    Calleja Chucla, Teresa
    Alonso De Castro, Beatriz
    Varela Ponte, Rafael
    Reboredo Rendo, Cristina
    Gomez-Randulfe Rodriguez, Martin Igor
    Silva Diaz, Sofia
    Grana Suarez, Begona
    de la Camara Gomez, Juan
    Busto Fernandez, Fernando
    Mateos Salvador, Maria
    Reboredo Lopez, Margarita
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [27] Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev): A real-world analysis
    Maddalena, Giulia
    van der Pol, Ymke
    Rivers, Zachary
    Dasari, Arvind
    Rogers, Jane E.
    Guinney, Justin
    Kopetz, Scott
    Raghav, Kanwal Pratap Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 201 - 201
  • [28] Multi-institutional analysis of real-world activity and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer
    Arrichiello, G.
    Martinelli, E.
    Troiani, T.
    Incoronato, P.
    Nacca, V.
    Paragliola, F.
    Napolitano, R.
    Suarato, G.
    Nicastro, A.
    Perrone, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S295 - S295
  • [29] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Nieves Martínez-Lago
    Teresa Calleja Chucla
    Beatriz Alonso De Castro
    Rafael Varela Ponte
    Cristina Reboredo Rendo
    Martin Igor Gomez-Randulfe Rodriguez
    Sofia Silva Diaz
    Begoña Graña Suarez
    Juan de la Cámara Gomez
    Fernando Busto Fernández
    María Mateos Salvador
    Margarita Reboredo Lopez
    Scientific Reports, 12
  • [30] Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study
    Patel, Anuj K.
    Ng, Kimmie
    Duh, Mei Sheng
    Barghout, Victoria E.
    Lynn Huynh
    Yenikomshian, Mihran Ara
    Sharperson, Camara
    Brais, Lauren K.
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345